DUSP26 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4048414	0.73	3/20
SCHEMBL4052471	0.69	3/20
SCHEMBL4052474	0.69	3/20
SCHEMBL4048608	0.65	3/20
SCHEMBL4048610	0.65	3/20
SCHEMBL4057079	0.62	3/20
SCHEMBL4057081	0.62	3/20
SCHEMBL4051099	0.61	3/20
SCHEMBL4051102	0.61	3/20
SCHEMBL4058782	0.61	3/20
SCHEMBL4058785	0.61	3/20
SCHEMBL4053756	0.61	3/20
SCHEMBL4056644	0.60	3/20
SCHEMBL4056648	0.60	3/20
SCHEMBL4058429	0.60	3/20
SCHEMBL4058432	0.60	3/20
SCHEMBL4049524	0.59	3/20
SCHEMBL4049525	0.59	3/20
SCHEMBL4060684	0.59	3/20
SCHEMBL4060687	0.59	3/20

Clinical trials — most relevant to DUSP26 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Molecular Mechanisms Underlying Prostate Cancer Disparities	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997	nan	COMPLETED
Cancer Fusion Hybrids and Desmoplasia	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP26 binder may also engage these)

Protein	Name	Similarity
Q5FVI9	—	1.000	Q5FVI9 →
Q5R6H6	—	1.000	Q5R6H6 →
Q9D700	—	1.000	Q9D700 →
Q17QJ3	—	0.999	Q17QJ3 →
Q6B8I1	—	0.986	Q6B8I1 →
Q6B8I0	—	0.981	Q6B8I0 →
P0C595	—	0.980	P0C595 →
Q68J44	—	0.980	Q68J44 →
Q8BK84	—	0.978	Q8BK84 →
P0C594	—	0.974	P0C594 →
P0C591	—	0.974	P0C591 →
O54838	—	0.973	O54838 →
P0C596	—	0.970	P0C596 →
P0C592	—	0.969	P0C592 →
Q29RA3	—	0.968	Q29RA3 →
DUSP5	Dual specificity protein phosphatase 5	0.968	landscape →
Q91ZT7	—	0.965	Q91ZT7 →
Q4RQD3	—	0.964	Q4RQD3 →
Q9PW71	—	0.962	Q9PW71 →
Q8K045	—	0.961	Q8K045 →
Q9JLY7	—	0.961	Q9JLY7 →
Q61152	—	0.961	Q61152 →
PTPN18	Tyrosine-protein phosphatase non-receptor type 18	0.961	landscape →
Q05922	—	0.960	Q05922 →
P0C5A0	—	0.960	P0C5A0 →
DUSP4	Dual specificity protein phosphatase 4	0.960	landscape →
P08923	—	0.958	P08923 →
Q16829	—	0.958	Q16829 →
PKN3	Serine/threonine-protein kinase N3	0.958	landscape →
Q6E804	—	0.958	Q6E804 →